GLP-1 RAs: Real-World Patient-Care Strategies for Type 2 Diabetes
This interactive, case-based activity provides education on the clinical characteristics of the GLP-1 RAs, how they differ from each other, and the rationale and guidance for their use with patients with Type 2 Diabetes (T2D). Participants will encounter clinical case scenarios on personalizing treatment with GLP-1 RAs, taking into account patient characteristics and preferences, adherence, and management of side effects.
At the end of this session, learners should be able to:
Differentiate available GLP-1 RAs based on therapy characteristics
Utilize patient preferences and available treatment guidelines to select optimal GLP-1 RA for patients with T2D
Implement strategies to manage potential side effects of GLP-1 RAs in the management of T2D
This activity is designed for family medicine physicians, and other primary care team members caring for patients with type 2 diabetes.
Participation and Credit:
Learners must register to participate in and receive credit for this online educational activity. Read the target audience, learning objectives, and author disclosures. Study the educational content online, complete all quizzes and scenario questions, and complete the activity evaluation. Your certificate will be available to you as a downloadable link. You may print the certificate, but you cannot alter it. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Unlabeled Use Disclosure:
This activity will not include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), and the curriculum clearly indicates this fact.
This activity is supported by an educational grant from Novo Nordisk.
There is no charge for this activity.
CAFP policy and California state law requires that each learning activity have elements of cultural and linguistic proficiency included in the content. The definition of cultural and linguistic competency is the ability and readiness of health care providers and health organizations to humbly and respectfully demonstrate, effectively communicate, and tailor delivery of care to patients with diverse values, beliefs, identities, and behaviors, in order to meet patients’ social, cultural, and linguistic needs as it relates to patient health. This activity meets these requirements.
CAFP policy and California state law requires that all CME activities comprising a patient care element include either (1) examples of how implicit bias affects perceptions and treatment decisions of physicians and surgeons, leading to disparities in health outcomes and/or (2) strategies to address how unintended biases in decision-making may contribute to health care disparities by shaping behavior and producing differences in medical treatment along lines of race, ethnicity, gender identity, sexual orientation, age, socioeconomic status, or other characteristics. This activity meets these requirements.
The California Academy of Family Physicians (CAFP) is committed to protecting the privacy of its members and customers. CAFP maintains safeguards to store and secure information it has about members and customers. The safeguards may be physical, electronic or procedural. For more information, contact email@example.com.
For questions regarding the content of this activity or for technical assistance, contact firstname.lastname@example.org.
The CAFP has made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education program. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the learner is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Approval of credit for this continuing education program does not imply endorsement by CAFP of any product or manufacturer identified.
Any medications or treatment methods suggested in this CME activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.
© 2023 California Academy of Family Physicians. No part of this activity may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.
Leslie Goldstein, PharmD, FNAOME
Assistant Professor of Pharmacology,
New York Institute of Technology,
Long Island, NY
Dr. Goldstein has no relationships with ineligible companies to disclose.
Jay H. Shubrook, DO, FAAFP, FACOFP
Jay Shubrook, DO, is a Board Certified family physician and a Fellowship trained Diabetologist. He is a Professor at Touro University California where he also serves as the Director of Diabetes Services. His research focus is on the prevention and early intervention for type 2 diabetes. His clinical and professional focus is on better training the primary care workforce to be prepared to help people manage diabetes. He is the Associate Editor of Clinical Diabetes and is the Chair of the Board of the American College of Diabetology- a new pathway to recognize primary care physicians who provide excellence in diabetes care. His book, "Everyday Diabetes: Case Studies in Primary Care,” was published in 2023.
Jay Shubrook, DO, serves or has recently served on the advisory boards of AstraZeneca, Bayer, Eli Lilly, and Nevro. He also serves as a consultant for Abbott Pharmaceuticals and Novo Nordisk. These relevant financial relationships have been mitigated.
Conflict of Interest Statements:
The CAFP Committee on Continuing Professional Development is responsible for management and resolution of conflict for any individual who may have influence on content, who have served as faculty, or who may produce or help produce CME/CPD content for the CAFP. Management/Resolution may include learner notification, peer review of content before presentation, changing topics, or even dismissing a potential faculty member.
It is the policy of the CAFP to ensure independence, balance, objectivity, scientific rigor, and integrity in all continuing education activities. All individuals with potential to influence the content of this program have submitted Conflict of Interest declarations that have been reviewed according to policy. Learner notification of declarations is below. All individuals with potential conflicts have been contacted by CAFP staff or CCPD members, and issues of conflict have been discussed, managed, and resolved.
The following planners have no relevant financial relationships to disclose: Laurie Isenberg, MA, MILS, Lindsay Aspaas, Emily Peck
1.00 AAFP Prescribed Credit
The AAFP has reviewed the enduring activity, GLP-1 RAs: Real-World Patient-Care Strategies for Type 2 Diabetes, and deemed it acceptable for up to 1.00 AAFP Prescribed credit. Term of Approval is from 10/20/2023 to 10/19/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed credit, not as Category 1.
- 1.00 AAFP Prescribed
- 1.00 AOA Category 2-A